Clinical Study

A Randomized Phase II Study Of Perioperative Mfolfirinox Versus Gemcitabine/Nab-Paclitaxel As Therapy For Resectable Pancreatic Adenocarcinoma.

Posted Date: Jul 6, 2017

  • Investigator: John Morris
  • Co-Investigator: Patricia Rose
  • Specialties: Gastroenterology, Hematology/Oncology, Oncology, Cancer, Surgical Oncology
  • Type of Study: Drug

to compare the effects of two different combinations of FDA-approved chemotherapy drugs. These two combinations are called mFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel. These chemotherapy drugs will be given

Criteria:

To Be Eligible For This Study, Patients Must Have Pancreatic Cancer That Can Be Removed By Surgery.

Keywords:

Pancreatic, S1505, Resectable, Cancer, Gastrointestinal

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.